| Indicators | Browse All

NuCana plc (NCNA)

Healthcare | Biotechnology | Edinburgh, United Kingdom | NasdaqCM
1.28 USD -0.06 (-4.478%) ⇩ (July 13, 2026, 4 p.m. EDT)
After hours: 1.29 +0.01 (0.930%) ⇧ (July 13, 2026, 7:14 p.m. EDT)

Short-term:★☆☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 4:07 a.m. EDT

The immediate outlook is severely clouded by a relentless downward trend that has persisted for seven consecutive years, culminating in a catastrophic 99.99% loss of value over the observation window. While the stock recently found a temporary floor near $1.24, the recent price action shows a sharp decline from mid-June highs of $1.83 to the current level, indicating continued selling pressure rather than a stabilization. The fundamental picture is dire, with negative earnings, negative free cash flow, and a return on equity that suggests the business is destroying capital. Although the balance sheet currently holds significant cash relative to debt, providing a theoretical buffer, the market has already priced in a complete failure of the company's core operations, evidenced by the near-total erasure of shareholder value. There is no evidence of a turnaround in revenue growth or operational efficiency to suggest a recovery is imminent. Consequently, the security offers no safe harbor for capital preservation, making it unsuitable for both short-term speculation and long-term holding.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.109408
AutoETS0.116282
AutoTheta0.118577
AutoARIMA0.177613

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 25%
H-stat 14.16
Ljung-Box p 0.000
Jarque-Bera p 0.006
Excess Kurtosis 0.77
Attribute Value
Sector Healthcare
Debt to Equity Ratio 3.04
Market Cap 5,327,323
Trailing P/E 0.01
Forward P/E -0.14
Beta 2.24
Website https://www.nucana.com

Info Dump

Attribute Value
52 Week Change -0.8543478
Address1 3 Lochside Way
All Time High 160,000.0
All Time Low 1.21
Ask 1.62
Ask Size 2
Average Daily Volume10 Day 88,390
Average Daily Volume3 Month 47,752
Average Volume 47,752
Average Volume10Days 88,390
Beta 2.236
Bid 0.9792
Bid Size 2
Book Value 7.086694
City Edinburgh
Compensation As Of Epoch Date 1,767,139,200
Country United Kingdom
Crypto Tradeable 0
Currency USD
Current Price 1.28
Current Ratio 5.482
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 1.365
Day Low 1.26
Debt To Equity 3.04
Display Name NuCana
Earnings Timestamp End 1,755,518,400
Earnings Timestamp Start 1,755,082,740
Ebitda -22,592,000
Ebitda Margins 0.0
Enterprise To Ebitda 0.687
Enterprise Value -15,521,805
Eps Forward -9.43
Eps Trailing Twelve Months 132.01
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 1.89
Fifty Day Average Change -0.61
Fifty Day Average Change Percent -0.32275134
Fifty Two Week Change Percent -85.434784
Fifty Two Week High 13.0
Fifty Two Week High Change -11.72
Fifty Two Week High Change Percent -0.9015385
Fifty Two Week Low 1.21
Fifty Two Week Low Change 0.06999993
Fifty Two Week Low Change Percent 0.057851184
Fifty Two Week Range 1.21 - 13.0
Financial Currency GBP
First Trade Date Milliseconds 1,506,605,400,000
Float Shares 4,161,580
Forward Eps -9.43
Forward P E -0.135737
Free Cashflow -3,203,750
Full Exchange Name NasdaqCM
Full Time Employees 10
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.000020000001
Held Percent Institutions 0.01382
Implied Shares Outstanding 4,161,971
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,754,870,400
Last Split Factor 1:200
Long Business Summary NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.
Long Name NuCana plc
Market us_market
Market Cap 5,327,323
Market State POSTPOST
Max Age 86,400
Message Board Id finmb_50918463
Most Recent Quarter 1,774,915,200
Net Income To Common -30,745,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 5,577,041
Open 1.35
Operating Cashflow -7,540,000
Operating Margins 0.0
Payout Ratio 0.0
Phone 44 13 1357 1111
Post Market Change 0.011900067
Post Market Change Percent 0.9296928
Post Market Price 1.2919
Post Market Time 1,783,984,442
Previous Close 1.34
Price Hint 4
Price To Book 0.1806202
Profit Margins 0.0
Quick Ratio 5.288
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.0600001
Regular Market Change Percent -4.47762
Regular Market Day High 1.365
Regular Market Day Low 1.26
Regular Market Day Range 1.26 - 1.365
Regular Market Open 1.35
Regular Market Previous Close 1.34
Regular Market Price 1.28
Regular Market Time 1,783,972,800
Regular Market Volume 40,739
Return On Assets -0.72796
Return On Equity -2.31679
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 4,161,971
Shares Percent Shares Out 0.0278
Shares Short 115,766
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 127,295
Short Name NuCana plc
Short Percent Of Float 0.0278
Short Ratio 2.46
Source Interval 15
Symbol NCNA
Total Cash 21,529,000
Total Cash Per Share 5.173
Total Debt 680,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps 132.01
Trailing P E 0.009696235
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 2.84835
Two Hundred Day Average Change -1.5683501
Two Hundred Day Average Change Percent -0.55061704
Type Disp Equity
Volume 40,739
Website https://www.nucana.com
Zip EH12 9DT